Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
Wu YL, John T, Grohe C, Majem M, Goldman JW, Kim SW, Kato T, Laktionov K, Vu HV, Wang Z, Lu S, Lee KY, Akewanlop C, Yu CJ, de Marinis F, Bonanno L, Domine M, Shepherd FA, Zeng L, Atasoy A, Herbst RS, Tsuboi M. Postoperative Chemotherapy Use and Outcomes From ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC. Journal Of Thoracic Oncology 2021, 17: 423-433. PMID: 34740861, DOI: 10.1016/j.jtho.2021.10.014.Peer-Reviewed Original ResearchConceptsAdjuvant chemotherapy useDisease-free survivalAdjuvant chemotherapyChemotherapy useStage IBDisease stageEGFRm NSCLCStage IIPostoperative chemotherapy usePrevious adjuvant chemotherapyADAURA studyAdjuvant osimertinibIIIA NSCLCAdjuvant therapyDFS benefitMedian durationPrespecified analysisPatient ageRecurrence rateEffective treatmentNSCLCChemotherapyPatientsMeaningful improvementsOsimertinibOA06.04 Postoperative Chemotherapy Use and Outcomes from ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR Mutated NSCLC
Wu Y, John T, Grohe C, Majem M, Goldman J, Kim S, Kato T, Laktionov K, Vu H, Wang Z, Lu S, Lee K, Akewanlop C, Yu C, De Marinis F, Bonanno L, Domine M, Shepherd F, Zeng L, Atasoy A, Herbst R, Tsuboi M. OA06.04 Postoperative Chemotherapy Use and Outcomes from ADAURA: Osimertinib as Adjuvant Therapy for Resected EGFR Mutated NSCLC. Journal Of Thoracic Oncology 2021, 16: s113-s114. DOI: 10.1016/j.jtho.2021.01.292.Peer-Reviewed Original Research